Humana to Buy Enclara Healthcare

January 5, 2020

The acquisition allows Humana to cover pharmacy-related needs associated with hospice care.

Humana Inc., Louisville, Kentucky, in December signed a definitive agreement to acquire privately held Enclara Healthcare, a hospice pharmacy and benefit management provider, from Consonance Capital Partners and Enclara management.

The acquisition provides Humana the opportunity to cover pharmacy-related needs associated with hospice care, simplify the mail order pharmacy experience, and advance its technology for in-home pharmacy through areas such as enhanced mobile medication management and improved electronic medical record (EMR) connectivity.

“Enclara represents a logical extension of Humana Pharmacy’s strategy given the company’s unique ability to play a role in advanced illness care and supplement our existing care delivery system,” says Scott Greenwell, PharmD, president, Humana Pharmacy Solutions. “We look forward to leveraging and expanding the capabilities of Enclara to further advance our clinical management expertise.”

Related: Partnership Plans to Improve Health Services for Aging Seniors

Enclara serves more than 450 hospice providers and 97,000 hospice patients per day through multiple, scalable models designed to fit unique customer needs.

“I am excited about the opportunity to work closely with Humana to carry on Enclara’s mission of serving as an invaluable resource to hospice providers,” says Andrew Horowitz, founder and CEO, Enclara Healthcare. “This combination will allow Enclara to accelerate innovation aimed at delivering timely and cost effective pharmacy solutions.”

The Enclara transaction, which includes acquisition of Enclara Pharmacia, GuidantRx, and Avanti Health Care Services, is anticipated to close during the first half of this year and is subject to customary state and federal regulatory approvals as well as other customary closing conditions. Financial terms of the transaction were not disclosed. The transaction is expected to have an immaterial impact to earnings in 2020.